NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
TEMPLE CITY, Calif., Oct. 26, 2016 -- Fulgent Genetics, Inc. (Nasdaq:FLGT) (“Fulgent Genetics” or the “company”) today announced that its third quarter 2016 financial results will be released after market close on Thursday, November 3, 2016. The company’s Chairman and Chief Executive Officer Ming Hsieh, its Chief Science Officer Dr. Harry Gao, and its Chief Financial Officer Paul Kim will host an investment community conference call the same day at 5:00 PM ET (2:00 PM PT) to discuss the results and answer questions.
The call can be accessed through a live audio webcast in the Investor Relations section of the company’s website, www.fulgentgenetics.com, and through a live conference call by calling 1-855-321-9535, passcode #96884184. An audio replay will be available on the company’s website or by calling 1-855-859-2056 through November 10, 2016.
About Fulgent Genetics, Inc.
Fulgent Genetics is a rapidly growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu, which includes more than 18,000 single-gene tests and more than 200 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.
Investor Contacts: The Blueshirt Group Bob Jones, 212-871-5570, [email protected] Chris Danne, 415-217-5865, [email protected]
